Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Assembly PCR synthesis of optimally designed, compact, multi-responsive promoters suited to gene therapy application.

Mohamed H, Chernajovsky Y, Gould D.

Sci Rep. 2016 Jul 8;6:29388. doi: 10.1038/srep29388.

2.

Effects of APC De-targeting and GAr modification on the duration of luciferase expression from plasmid DNA delivered to skeletal muscle.

Subang MC, Fatah R, Wu Y, Hannaman D, Rice J, Evans CF, Chernajovsky Y, Gould D.

Curr Gene Ther. 2015;15(1):3-14.

3.
4.

Growth associated protein (GAP-43): cloning and the development of a sensitive ELISA for neurological disorders.

Gnanapavan S, Yousaf N, Heywood W, Grant D, Mills K, Chernajovsky Y, Keir G, Giovannoni G.

J Neuroimmunol. 2014 Nov 15;276(1-2):18-23. doi: 10.1016/j.jneuroim.2014.07.008. Epub 2014 Jul 23.

PMID:
25175067
5.

Latent cytokines for targeted therapy of inflammatory disorders.

Mullen L, Adams G, Layward L, Vessillier S, Annenkov A, Mittal G, Rigby A, Sclanders M, Baker D, Gould D, Chernajovsky Y.

Expert Opin Drug Deliv. 2014 Jan;11(1):101-10. doi: 10.1517/17425247.2014.863872. Epub 2013 Dec 3. Review.

PMID:
24294995
6.

Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β.

Mullen L, Rigby A, Sclanders M, Adams G, Mittal G, Colston J, Fatah R, Subang C, Foster J, Francis-West P, Köster M, Hauser H, Layward L, Vessillier S, Annenkov A, Al-Izki S, Pryce G, Bolton C, Baker D, Gould DJ, Chernajovsky Y.

Expert Opin Drug Deliv. 2014 Jan;11(1):5-16. doi: 10.1517/17425247.2013.839655. Epub 2013 Sep 27.

PMID:
24073618
7.

Generation of an efficiently secreted, cell penetrating NF-κB inhibitor.

Koutsokeras A, Purkayastha N, Rigby A, Subang MC, Sclanders M, Vessillier S, Mullen L, Chernajovsky Y, Gould D.

FASEB J. 2014 Jan;28(1):373-81. doi: 10.1096/fj.13-236570. Epub 2013 Sep 26. Erratum in: FASEB J. 2014 Jun;28(6):2737. Purkayashta, Nirupam [corrected to Purkayastha, Nirupam].

PMID:
24072781
8.

Erythropoietin (EPO) increases myelin gene expression in CG4 oligodendrocyte cells through the classical EPO receptor.

Cervellini I, Annenkov A, Brenton T, Chernajovsky Y, Ghezzi P, Mengozzi M.

Mol Med. 2013 Aug 28;19:223-9. doi: 10.2119/molmed.2013.00013.

9.

A comparative study of matrix metalloproteinase and aggrecanase mediated release of latent cytokines at arthritic joints.

Mullen L, Adams G, Foster J, Vessillier S, Köster M, Hauser H, Layward L, Gould D, Chernajovsky Y.

Ann Rheum Dis. 2014 Sep;73(9):1728-36. doi: 10.1136/annrheumdis-2013-203513. Epub 2013 Jun 27.

PMID:
23813971
10.

Therapeutic improvement of a stroma-targeted CRAd by incorporating motives responsive to the melanoma microenvironment.

Viale DL, Cafferata EG, Gould D, Rotondaro C, Chernajovsky Y, Curiel DT, Podhajcer OL, Veronica Lopez M.

J Invest Dermatol. 2013 Nov;133(11):2576-2584. doi: 10.1038/jid.2013.191. Epub 2013 Apr 19.

11.

Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide.

Wythe SE, DiCara D, Taher TE, Finucane CM, Jones R, Bombardieri M, Man YK, Nissim A, Mather SJ, Chernajovsky Y, Pitzalis C.

Ann Rheum Dis. 2013 Jan;72(1):129-35. doi: 10.1136/annrheumdis-2012-201457. Epub 2012 Jul 27.

12.

Increased disulphide dimer formation of latent associated peptide fusions of TGF-β by addition of L-cystine.

Mullen LM, Adams G, Chernajovsky Y.

J Biotechnol. 2012 Oct 31;161(3):269-77. doi: 10.1016/j.jbiotec.2012.07.003. Epub 2012 Jul 23.

PMID:
22835852
13.

Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke.

Mengozzi M, Cervellini I, Villa P, Erbayraktar Z, Gökmen N, Yilmaz O, Erbayraktar S, Manohasandra M, Van Hummelen P, Vandenabeele P, Chernajovsky Y, Annenkov A, Ghezzi P.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9617-22. doi: 10.1073/pnas.1200554109. Epub 2012 May 29.

14.

A novel hybrid promoter responsive to pathophysiological and pharmacological regulation.

Subang MC, Fatah R, Bright C, Blanco P, Berenstein M, Wu Y, Podhajcer OL, Winyard PG, Chernajovsky Y, Gould D.

J Mol Med (Berl). 2012 Apr;90(4):401-11. doi: 10.1007/s00109-011-0826-3. Epub 2011 Oct 30.

15.

Molecular engineering of short half-life small peptides (VIP, αMSH and γ₃MSH) fused to latency-associated peptide results in improved anti-inflammatory therapeutics.

Vessillier S, Adams G, Montero-Melendez T, Jones R, Seed M, Perretti M, Chernajovsky Y.

Ann Rheum Dis. 2012 Jan;71(1):143-9. doi: 10.1136/annrheumdis-2011-200100. Epub 2011 Oct 13.

PMID:
21998117
16.

The importance of understanding the molecular mechanisms of resistance to biologics.

Chernajovsky Y.

Rheumatology (Oxford). 2012 Mar;51(3):397-8. doi: 10.1093/rheumatology/ker313. Epub 2011 Oct 8. No abstract available.

PMID:
21984767
17.

Comment on: Low TNF-induced NF-κB and p38 phosphorylation levels in leucocytes in tumour necrosis factor receptor-associated periodic syndrome.

Turner MD, Chernajovsky Y.

Rheumatology (Oxford). 2011 Aug;50(8):1525-6; author reply 1526-9. doi: 10.1093/rheumatology/ker145. Epub 2011 Jun 14. No abstract available.

PMID:
21672967
18.

A chimeric receptor of the insulin-like growth factor receptor type 1 (IGFR1) and a single chain antibody specific to myelin oligodendrocyte glycoprotein activates the IGF1R signalling cascade in CG4 oligodendrocyte progenitors.

Annenkov A, Rigby A, Amor S, Zhou D, Yousaf N, Hemmer B, Chernajovsky Y.

Biochim Biophys Acta. 2011 Aug;1813(8):1428-37. doi: 10.1016/j.bbamcr.2011.04.006. Epub 2011 May 4.

19.

Human single-chain variable fragment that specifically targets arthritic cartilage.

Hughes C, Faurholm B, Dell'Accio F, Manzo A, Seed M, Eltawil N, Marrelli A, Gould D, Subang C, Al-Kashi A, De Bari C, Winyard P, Chernajovsky Y, Nissim A.

Arthritis Rheum. 2010 Apr;62(4):1007-16. doi: 10.1002/art.27346.

20.

Quantitative imaging of cartilage and bone for functional assessment of gene therapy approaches in experimental arthritis.

Stok KS, Noël D, Apparailly F, Gould D, Chernajovsky Y, Jorgensen C, Müller R.

J Tissue Eng Regen Med. 2010 Jul;4(5):387-94. doi: 10.1002/term.251.

PMID:
20101620
21.

Dual luciferase labelling for non-invasive bioluminescence imaging of mesenchymal stromal cell chondrogenic differentiation in demineralized bone matrix scaffolds.

Vilalta M, Jorgensen C, Dégano IR, Chernajovsky Y, Gould D, Noël D, Andrades JA, Becerra J, Rubio N, Blanco J.

Biomaterials. 2009 Oct;30(28):4986-95. doi: 10.1016/j.biomaterials.2009.05.056. Epub 2009 Jun 17.

PMID:
19539363
22.

Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses.

Lopez MV, Viale DL, Cafferata EG, Bravo AI, Carbone C, Gould D, Chernajovsky Y, Podhajcer OL.

PLoS One. 2009;4(4):e5119. doi: 10.1371/journal.pone.0005119. Epub 2008 Apr 8.

23.

Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging.

Vilalta M, Dégano IR, Bagó J, Gould D, Santos M, García-Arranz M, Ayats R, Fuster C, Chernajovsky Y, García-Olmo D, Rubio N, Blanco J.

Stem Cells Dev. 2008 Oct;17(5):993-1003. doi: 10.1089/scd.2007.0201.

PMID:
18537463
24.

Fibroblast-mediated delivery of GDNF induces neuronal-like outgrowth in PC12 cells.

Wissel K, Stöver T, Hofmann NS, Chernajovsky Y, Daly G, Sasse S, Warnecke A, Lenarz T, Gross G, Hoffmann A.

Otol Neurotol. 2008 Jun;29(4):475-81. doi: 10.1097/MAO.0b013e318164d110.

PMID:
18520583
25.

Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome.

Nedjai B, Hitman GA, Yousaf N, Chernajovsky Y, Stjernberg-Salmela S, Pettersson T, Ranki A, Hawkins PN, Arkwright PD, McDermott MF, Turner MD.

Arthritis Rheum. 2008 Jan;58(1):273-83. doi: 10.1002/art.23123.

26.

Historical development of monoclonal antibody therapeutics.

Nissim A, Chernajovsky Y.

Handb Exp Pharmacol. 2008;(181):3-18. Review.

PMID:
18071939
27.

Novel delivery methods to achieve immunomodulation.

Gould DJ, Chernajovsky Y.

Curr Opin Pharmacol. 2007 Aug;7(4):445-50. Epub 2007 Jul 3. Review.

28.

Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis.

Khoury M, Adriaansen J, Vervoordeldonk MJ, Gould D, Chernajovsky Y, Bigey P, Bloquel C, Scherman D, Tak PP, Jorgensen C, Apparailly F.

J Gene Med. 2007 Jul;9(7):596-604.

PMID:
17514770
29.

Engineering stem cells for therapy.

Mendez-Pertuz M, Hughes C, Annenkov A, Daly G, Chernajovsky Y.

Regen Med. 2006 Jul;1(4):575-87. Review.

PMID:
17465851
30.

Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent.

Adriaansen J, Khoury M, de Cortie CJ, Fallaux FJ, Bigey P, Scherman D, Gould DJ, Chernajovsky Y, Apparailly F, Jorgensen C, Vervoordeldonk MJ, Tak PP.

Ann Rheum Dis. 2007 Sep;66(9):1143-50. Epub 2007 Mar 15.

31.
32.

The differential expression of corticosteroid receptor isoforms in corticosteroid-resistant and -sensitive patients with rheumatoid arthritis.

Kozaci DL, Chernajovsky Y, Chikanza IC.

Rheumatology (Oxford). 2007 Apr;46(4):579-85. Epub 2006 Oct 13.

PMID:
17043048
33.

Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth.

Lopez MV, Blanco P, Viale DL, Cafferata EG, Carbone C, Gould D, Chernajovsky Y, Podhajcer OL.

Mol Cancer Ther. 2006 Oct;5(10):2503-11.

34.

Fighting cancer with oncolytic viruses.

Chernajovsky Y, Layward L, Lemoine N.

BMJ. 2006 Jan 21;332(7534):170-2. Review. No abstract available.

35.

Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint.

Nissim A, Winyard PG, Corrigall V, Fatah R, Perrett D, Panayi G, Chernajovsky Y.

Arthritis Rheum. 2005 Dec;52(12):3829-38.

36.

Gene therapy for arthritis--where do we stand?

Chernajovsky Y.

Arthritis Res Ther. 2005;7(6):227-9. Epub 2005 Sep 14.

37.

IL-12 and IL-10 expression synergize to induce the immune-mediated eradication of established colon and mammary tumors and lung metastasis.

Lopez MV, Adris SK, Bravo AI, Chernajovsky Y, Podhajcer OL.

J Immunol. 2005 Nov 1;175(9):5885-94.

38.

Regulation of expression and function of Lck tyrosine kinase by high cell density.

Ozegbe P, Chernajovsky Y, Kabouridis PS.

Mol Membr Biol. 2005 Jul-Aug;22(4):363-72.

39.
40.

The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation.

Inglis JJ, Nissim A, Lees DM, Hunt SP, Chernajovsky Y, Kidd BL.

Arthritis Res Ther. 2005;7(4):R807-16. Epub 2005 Apr 12.

41.

Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3.

Vessillier S, Adams G, Chernajovsky Y.

Protein Eng Des Sel. 2004 Dec;17(12):829-35. Epub 2005 Feb 11.

PMID:
15708865
42.

Gene therapy for autoimmune diseases: quo vadis?

Chernajovsky Y, Gould DJ, Podhajcer OL.

Nat Rev Immunol. 2004 Oct;4(10):800-11. Review.

PMID:
15459671
43.

Prevention of experimental autoimmune encephalomyelitis in DA rats by grafting primary skin fibroblasts engineered to express transforming growth factor-beta1.

Zargarova T, Kulakova O, Prassolov V, Zharmukhamedova T, Tsyganova V, Turobov V, Ivanov D, Parfenov M, Sudomoina M, Chernajovsky Y, Favorova O.

Clin Exp Immunol. 2004 Aug;137(2):313-9.

45.

Methods for targeting biologicals to specific disease sites.

Nissim A, Gofur Y, Vessillier S, Adams G, Chernajovsky Y.

Trends Mol Med. 2004 Jun;10(6):269-74. Review.

PMID:
15177191
46.
47.

Targeting therapeutic molecules to sites of disease.

Chernajovsky Y, Vessillier S, Adams G.

Discov Med. 2004 Feb;4(20):30-2.

48.

T cell receptor zeta reconstitution fails to restore responses of T cells rendered hyporesponsive by tumor necrosis factor alpha.

Clark JM, Annenkov AE, Panesar M, Isomäki P, Chernajovsky Y, Cope AP.

Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1696-701. Epub 2004 Jan 26.

49.

Development of new molecules, vectors and cells for therapy of arthritis.

Chernajovsky Y, Vessillier S, Adams G, Gofur Y, Subang MC, Annenkov A, Favorov P, Daly G, Gould D.

Joint Bone Spine. 2003 Dec;70(6):474-6. No abstract available.

PMID:
14667556
50.

The molecular and cellular basis of corticosteroid resistance.

Chikanza IC, Kozaci D, Chernajovsky Y.

J Endocrinol. 2003 Dec;179(3):301-10. Review.

Supplemental Content

Loading ...
Support Center